272 related articles for article (PubMed ID: 17879368)
1. Very low human Papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests.
Zhao C; Elishaev E; Yuan KH; Yu J; Austin RM
Cancer; 2007 Oct; 111(5):292-7. PubMed ID: 17879368
[TBL] [Abstract][Full Text] [Related]
2. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples.
Cibas ES; Hong X; Crum CP; Feldman S
Gynecol Oncol; 2007 Mar; 104(3):702-6. PubMed ID: 17150245
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zone.
Zhao C; Austin RM
Gynecol Oncol; 2007 Nov; 107(2):231-5. PubMed ID: 17854873
[TBL] [Abstract][Full Text] [Related]
4. High-risk HPV DNA detected in less than 2% of over 25,000 cytology negative imaged liquid-based Pap test samples from women 30 and older.
Bansal M; Austin RM; Zhao C
Gynecol Oncol; 2009 Nov; 115(2):257-61. PubMed ID: 19665217
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample.
Zhao C; Austin RM
Cancer; 2008 Aug; 114(4):242-8. PubMed ID: 18484643
[TBL] [Abstract][Full Text] [Related]
6. Resolution of equivocal results with the Hybrid Capture II high-risk HPV DNA test: a cytologic/histologic review of 191 cases.
Knoepp SM; Kuebler DL; Wilbur DC
Diagn Mol Pathol; 2007 Sep; 16(3):125-9. PubMed ID: 17721319
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ThinPrep and SurePath liquid-based cytology and subsequent human papillomavirus DNA testing in China.
Zhao FH; Hu SY; Bian JJ; Liu B; Peck RB; Bao YP; Pan QJ; Frappart L; Sellors J; Qiao YL
Cancer Cytopathol; 2011 Dec; 119(6):387-94. PubMed ID: 21774094
[TBL] [Abstract][Full Text] [Related]
8. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
9. Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma.
Li Z; Austin RM; Guo M; Zhao C
Arch Pathol Lab Med; 2012 Dec; 136(12):1533-40. PubMed ID: 22900617
[TBL] [Abstract][Full Text] [Related]
10. Detection of 14 human papillomavirus genotypes in cervical samples in women from a central-southern area of Italy showing different Pap test results.
Zappacosta B; Romano L; Guerriero M; Graziano M; Vitrani A; De Ninno M; Carbone A
New Microbiol; 2009 Oct; 32(4):351-8. PubMed ID: 20128441
[TBL] [Abstract][Full Text] [Related]
11. HPV DNA testing of the residual sample of liquid-based Pap test: utility as a quality assurance monitor.
Zuna RE; Moore W; Dunn ST
Mod Pathol; 2001 Mar; 14(3):147-51. PubMed ID: 11266518
[TBL] [Abstract][Full Text] [Related]
12. Reflex human papillomavirus DNA testing on residual liquid-based (TPPT) cervical samples: focus on age-stratified clinical performance.
Sarode VR; Werner C; Gander R; Foster B; Fulmer A; Saboorian MH; Ashfaq R
Cancer; 2003 Jun; 99(3):149-55. PubMed ID: 12811855
[TBL] [Abstract][Full Text] [Related]
13. Molecular testing of human papillomavirus in cervical specimens.
Gazzaz FB
Saudi Med J; 2007 Dec; 28(12):1810-8. PubMed ID: 18060207
[TBL] [Abstract][Full Text] [Related]
14. Cytologic diagnosis of atypical squamous cells of undetermined significance in perimenopausal and postmenopausal women: lessons learned from human Papillomavirus DNA testing.
Johnston EI; Logani S
Cancer; 2007 Jun; 111(3):160-5. PubMed ID: 17506090
[TBL] [Abstract][Full Text] [Related]
15. Follow-up outcomes of a large cohort of low-risk women with negative imaged liquid-based cytology and negative HPV test results.
Zhao C; Weng B; Li Z; Yang H; Austin RM
Am J Clin Pathol; 2013 Jan; 139(1):32-8. PubMed ID: 23270896
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus detection: verification with cervical cytology.
Matthews-Greer J; Rivette D; Reyes R; Vanderloos CF; Turbat-Herrera EA
Clin Lab Sci; 2004; 17(1):8-11. PubMed ID: 15011974
[TBL] [Abstract][Full Text] [Related]
17. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.
Wright TC; Schiffman M; Solomon D; Cox JT; Garcia F; Goldie S; Hatch K; Noller KL; Roach N; Runowicz C; Saslow D
Obstet Gynecol; 2004 Feb; 103(2):304-9. PubMed ID: 14754700
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis.
Gupta S; Sodhani P; Sharma A; Sharma JK; Halder K; Charchra KL; Sardana S; Singh V; Sehgal A; Das BC
Cytopathology; 2009 Aug; 20(4):249-55. PubMed ID: 19018810
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of high-risk human papillomavirus in women with abnormal and normal vaginal ThinPrep Papanicolaou cytology.
Bansal M; Zhao C
J Low Genit Tract Dis; 2011 Apr; 15(2):105-9. PubMed ID: 21317806
[TBL] [Abstract][Full Text] [Related]
20. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]